{
    "clinical_study": {
        "@rank": "32031", 
        "arm_group": {
            "arm_group_label": "Treatment (semaxanib)", 
            "arm_group_type": "Experimental", 
            "description": "Patients receive SU5416 IV over 1 hour twice weekly. Treatment continues every 6 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity. Patients with CR receive an additional 6 months of therapy after achieving CR."
        }, 
        "brief_summary": {
            "textblock": "Phase II trial to study the effectiveness of SU5416 in treating patients who have metastatic\n      kidney cancer that has not responded to previous therapy with interleukin-2. SU5416 may stop\n      the growth of kidney cancer by stopping blood flow to the tumor"
        }, 
        "brief_title": "SU5416 in Treating Patients With Metastatic Kidney Cancer That Has Not Responded to Previous Treatment", 
        "condition": [
            "Recurrent Renal Cell Cancer", 
            "Stage IV Renal Cell Cancer"
        ], 
        "condition_browse": {
            "mesh_term": "Carcinoma, Renal Cell"
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n      I. Determine the clinical activity of SU5416 in patients with progressive metastatic renal\n      cancer failing prior biologic therapy or fluorouracil-containing regimens.\n\n      II. Determine the changes in tumor perfusion in patients treated with this regimen.\n\n      III. Determine the time to progression and survival in patients treated with this regimen.\n\n      OUTLINE:\n\n      Patients receive SU5416 IV over 1 hour twice weekly. Treatment continues every 6 weeks for\n      at least 2 courses in the absence of disease progression or unacceptable toxicity. Patients\n      with complete response (CR) receive an additional 6 months of therapy after achieving CR.\n\n      Patients are followed every 3 months."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically confirmed metastatic renal cell carcinoma\n\n          -  Prior removal of primary tumors\n\n          -  Bidimensionally measurable disease\n\n               -  Bone-only disease is not considered measurable\n\n          -  Progressive disease following no more than 2 prior biologic therapy\n             (e.g.,interleukin-2, interferon alfa, vaccine, or dendritic cell therapy)\n             orfluorouracil-containing (single-agent or in combination therapy) regimens\n\n          -  No known history of CNS metastasis unless all of the following are true:\n\n               -  Previously treated\n\n               -  Neurologically stable\n\n               -  No requirement for IV steroids or anticonvulsants\n\n               -  No requirement for oral steroids and no evidence of active or residual CNS\n                  disease on CT scan or MRI\n\n          -  Negative brain scan (CT scan or MRI) required if neurologic signs or symptoms\n             suggestive of CNS metastasis present\n\n          -  Performance status - Zubrod 0-2\n\n          -  At least 12 weeks\n\n          -  Absolute neutrophil count at least 1,500/mm^3\n\n          -  Platelet count greater than 100,000/mm^3\n\n          -  Bilirubin no greater than 1.5 mg/dL\n\n          -  SGPT no greater than 2.5 times upper limit of normal\n\n          -  PT and PTT normal\n\n          -  Fibrinogen normal\n\n          -  D-Dimer assay normal\n\n          -  Creatinine no greater than 1.5 mg/dL\n\n          -  Creatinine clearance at least 60 mL/min\n\n          -  See Surgery\n\n          -  No active congestive heart failure\n\n          -  No uncontrolled angina\n\n          -  No myocardial infarction or severe/unstable angina within the past 6 months\n\n          -  No uncontrolled hypertension\n\n          -  No uncompensated coronary artery disease on electrocardiogram or physical examination\n\n          -  No severe peripheral vascular disease\n\n          -  No deep vein or arterial thrombosis within the past 3 months\n\n          -  No pulmonary embolism within the past 3 months\n\n          -  Not pregnant or nursing\n\n          -  Negative pregnancy test\n\n          -  Fertile patients must use effective contraception\n\n          -  No concurrent serious infection\n\n          -  No overt psychosis, mental disability, or incompetence\n\n          -  No diabetes mellitus\n\n          -  No other prior malignancy within the past 5 years except curatively treated\n             nonmelanoma skin cancer or carcinoma in situ of the cervix\n\n          -  No hypersensitivity or allergic reaction to paclitaxel\n\n          -  See Disease Characteristics\n\n          -  No other concurrent anti-cancer biologic therapy\n\n          -  See Disease Characteristics\n\n          -  No concurrent anti-cancer chemotherapy\n\n          -  See Disease Characteristics\n\n          -  At least 4 weeks since prior radiotherapy and recovered\n\n          -  No sole indicator lesion within the previously irradiated port\n\n          -  No concurrent anti-cancer radiotherapy\n\n          -  See Disease Characteristics\n\n          -  At least 4 weeks since prior major surgery and recovered\n\n          -  At least 1 year since prior bypass surgery for atherosclerotic coronary artery\n             disease\n\n          -  No concurrent surgery for cancer\n\n          -  No other investigational drugs (e.g., analgesics or antiemetics) for at least 28 days\n             prior to and after study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "16 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 2, 2001", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00009919", 
            "org_study_id": "NCI-2012-02373", 
            "secondary_id": [
                "ID99-291", 
                "N01CM17003", 
                "CDR0000068424"
            ]
        }, 
        "intervention": {
            "arm_group_label": "Treatment (semaxanib)", 
            "description": "Given IV", 
            "intervention_name": "semaxanib", 
            "intervention_type": "Drug", 
            "other_name": [
                "semoxind", 
                "SU5416", 
                "Sugen 5416"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": "SU 5416"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "January 22, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Houston", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "77030"
                }, 
                "name": "M D Anderson Cancer Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase II Study of SU5416 (NSC 696819) for Patients With Progressive Metastatic Renal Cancer Failing Prior Biologic Therapy or 5-Fluorouracil Containing Regimens", 
        "overall_official": {
            "affiliation": "M.D. Anderson Cancer Center", 
            "last_name": "Arlene Siefker-Radtke", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Terminated", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2003", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "Estimated with associated confidence intervals using standard methods such as chi-square and Fisher's exact tests.", 
                "measure": "Rate of progression-free events", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Estimated with associated confidence intervals using standard methods such as chi-square and Fisher's exact tests.", 
                "measure": "Objective response rate", 
                "safety_issue": "No", 
                "time_frame": "Up to 3 years"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00009919"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Analyzed using Kaplan Meier curves and Cox proportional hazards models.", 
                "measure": "Survival", 
                "safety_issue": "No", 
                "time_frame": "Up to 3 years"
            }, 
            {
                "description": "Analyzed using Kaplan Meier curves and Cox proportional hazards.", 
                "measure": "Time to disease progression", 
                "safety_issue": "No", 
                "time_frame": "Up to 3 years"
            }, 
            {
                "description": "Analyzed using Kaplan Meier curves and Cox proportional hazards.", 
                "measure": "Time to treatment failure", 
                "safety_issue": "No", 
                "time_frame": "Up to 3 years"
            }, 
            {
                "description": "Analyzed using Kaplan Meier curves and Cox proportional hazards.", 
                "measure": "Duration of response", 
                "safety_issue": "No", 
                "time_frame": "Up to 3 years"
            }
        ], 
        "source": "National Cancer Institute (NCI)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "December 2000", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2013", 
        "why_stopped": "Administratively complete."
    }, 
    "geocoordinates": {
        "M D Anderson Cancer Center": "29.76 -95.369"
    }
}